Healthcare, Regulatory and Reimbursement Landscape - Venezuela
Upcoming SlideShare
Loading in...5
×
 

Healthcare, Regulatory and Reimbursement Landscape - Venezuela

on

  • 262 views

 

Statistics

Views

Total Views
262
Views on SlideShare
262
Embed Views
0

Actions

Likes
0
Downloads
0
Comments
0

0 Embeds 0

No embeds

Accessibility

Categories

Upload Details

Uploaded via as Adobe PDF

Usage Rights

© All Rights Reserved

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Processing…
Post Comment
Edit your comment

Healthcare, Regulatory and Reimbursement Landscape - Venezuela Healthcare, Regulatory and Reimbursement Landscape - Venezuela Document Transcript

  • Healthcare, Regulatory and Reimbursement Landscape -VenezuelaReport Details:Published:December 2012No. of Pages: 149Price: Single User License – US$1995Healthcare, Regulatory and Reimbursement Landscape - VenezuelaSummaryGlobalData, the industry analysis specialist, has released its new report, “Healthcare, Regulatoryand Reimbursement Landscape - Venezuela”. The report is an essential source of information andanalysis on the healthcare, regulatory and reimbursement landscape of Venezuela. The reportidentifies the key trends in the healthcare market of Venezuela. The report also provides insightsinto the demographic, regulatory and reimbursement landscapes and the healthcare infrastructureof Venezuela. Most importantly, the report provides valuable insights into the trends andsegmentation of the pharmaceutical market. This report is built using data and information sourcedfrom proprietary databases, secondary research and in-house analysis by GlobalData’s team ofindustry experts.Venezuela was the 45th most populated country in the world with a population of approximately 28million in 2012. The population of Venezuela is increasing due to the high birth rate and lowmortality rate as well as an increase in life expectancy. The increase in the working-age populationsupports the country in its development while the increasing elderly population is a matter ofconcern for policy planners. The pharmaceutical market in Venezuela was estimated at $7 billionin 2011 and is expected to reach approximately $35.2 billion by 2020 at a projected CompoundAnnual Growth Rate (CAGR) of 19.7% between 2012 and 2020. However, the Venezuelancurrency was depreciated by the government for pharmaceutical products in 2011. Therefore,GlobalData estimates that the pharmaceutical market will be depreciated and valued at $4.2 billionin 2011, and will reach $8.5 billion in 2020 at a CAGR of 8.2% from 2006 to 2020.The positive trend in the healthcare market of Venezuela can be attributed primarily to -- The increasing elderly population- Increasing access to healthcare facilities- Government initiatives in the healthcare sector
  • - The increasing affordability of healthcareScopeThe report provides information on the healthcare, regulatory and reimbursement landscape ofVenezuela. The scope includes -- An overview of the pharmaceutical market of Venezuela including the market size, marketsegmentation, key drivers and barriers for the market.- Profile and SWOT analysis of the major players in the pharmaceutical market. Key playerscovered for the pharmaceutical market are Pfizer, GlaxoSmithKline, Sanofi, Novartis and GroupoFarma.- An insightful review on the reimbursement and regulatory landscape. Analysis includes details ofthe healthcare reimbursement process, regulatory agencies and the marketing authorizationprocess for new drugs and medical devices for Venezuela.- A detailed analysis of the political and economic environment of Venezuela, including theeconomic indicators, demographics, healthcare infrastructure and healthcare expenditure.- An overview of the opportunities and challenges for growth that exist in the healthcare market ofVenezuela.Reasons to buyThis report comprehensively covers the pharmaceutical market of Venezuela. The report willenhance your decision making capability. It will allow you to -- Develop business strategies by understanding the trends shaping and driving the healthcaremarket of Venezuela.- Drive revenues by understanding the key trends, reimbursement and regulatory policies,pharmaceutical market segments and companies likely to impact the Venezuelan healthcaremarket in future.- Formulate effective sales and marketing strategies by understanding the competitive landscapeand by analyzing the performance of various competitors.- Organize your sales and marketing efforts by identifying the market categories and segmentsthat present the biggest opportunities for consolidations, investments and strategic partnerships.- Identify, understand and capitalize on the opportunities and challenges in the healthcare marketof Venezuela.Get your copy of this report @http://www.reportsnreports.com/reports/209354-healthcare-regulatory-and-reimbursement-landscape-venezuela.htmlMajor points covered in Table of Contents of this report include1 Table of Contents1 Table of Contents 51.1 List of Tables 7
  • 1.2 List of Figures 82 Introduction 102.1 Report Guidance 103 Overview of the Pharmaceutical and Medical Devices Market 113.1 Pharmaceutical Market 113.1.1 Market Overview 113.1.2 Supply Channels 143.1.3 Market Segments 163.1.4 Major Disease Areas 193.1.5 Major Players 203.2 Medical Device Market 463.2.1 Market Overview 463.3 Market Drivers and Barriers 463.3.1 Drivers 463.3.2 Barriers 474 Market Access 494.1 Reimbursement and Payer Landscape 494.1.1 Reimbursement Process 524.1.2 Overview of Insurance Providers 534.1.3 Patient Share in Healthcare Spending 544.1.4 Price Trend for Medicines 554.2 Regulatory Landscape 564.2.1 Overview of Regulatory Agencies 564.2.2 Registration Procedure for New Drug 564.2.3 Medical Device Approval Process 584.2.4 Licensing Process for Pharmaceutical Manufacturing 584.2.5 Licensing Process for Pharmaceutical Exports and Imports 594.2.6 Intellectual Property Rights 594.2.7 Clinical Trial Regulations 644.2.8 Pharmaceutical Advertising Regulations 664.2.9 Pharmacy Regulations 674.2.10 Labeling and Packaging Regulations 685 Country Analysis 705.1 Political Environment 705.1.1 Political Structure 705.1.2 Analysis of the Current Political Environment 715.1.3 Healthcare Policy Initiatives 725.2 Economic Landscape 725.3 Economic Indicators 745.3.1 Gross Domestic Product 745.3.2 Gross National Income 785.3.3 Inflation 79
  • 5.3.4 Currency Exchange Rate 835.3.5 Foreign Direct Investment 855.3.6 Foreign Exchange Reserves 865.3.7 Trade Balance 875.3.8 Government Structural Balance 895.3.9 Government Gross Debt 915.3.10 Major Industries 935.4 Demography 945.4.1 Population 945.4.2 Education and Literacy 1135.4.3 Employment 1155.4.4 Disease Burden 1175.5 Healthcare Infrastructure 1185.5.1 Healthcare Facilities 1185.5.2 Healthcare Parameters 1245.5.3 Environmental Health 1265.6 Healthcare Expenditure 1305.6.1 Overview 1305.6.2 Share of Public and Private Sectors 1315.6.3 Spending in Healthcare R&D 1315.7 Trade Associations 1325.7.1 Venezuelan Chamber of Medicine 1325.7.2 Chamber of Pharmaceutical Industry 1325.7.3 Chamber of Non-prescription Medicines 1325.7.4 Venezuelan Association of Distributors of Medical Equipment, Dental Laboratories and Allied1325.7.5 Venezuelan Chamber of Pharmacy 1326 Opportunities and Challenges 1336.1 Opportunities 1336.2 Challenges 1347 Appendix 1367.1 Abbreviations 1367.2 Bibliography 1397.3 -Methodology 1477.3.1 Coverage 1477.3.2 Secondary Research 1477.3.3 Forecasting 1487.3.4 Primary Research 1487.3.5 Expert Panel Validation 1487.4 Contact Us 1487.5 Disclaimer 149
  • 1.1 List of TablesTable 1: Pharmaceutical Market ($bn), Venezuela, 2006-2011 12Table 2: Pharmaceutical Market ($bn), Venezuela, Forecast, 2012-2020 13Table 3: Drugs Going Off-patent, Revenues ($bn), Global, 2011-2015 17Table 4: Major Products, Pfizer, Global, Revenue ($m), 2011 21Table 5: Late-stage Pipeline, Pfizer, 2012 21Table 6: Major Products, GlaxoSmithKline, Global, Revenue ($m), 2011 26Table 7: Late Stage Pipeline, GlaxoSmithKline, 2012 27Table 8: Major Products, Sanofi, Global, Revenue ($m), 2011 32Table 9: Late-stage Pipeline, Sanofi, 2012 33Table 10: Major Products, Novartis, Global, Revenue ($m), 2011 37Table 11: Planned Filings, Novartis, 2012-2016 38Table 12: Major Products, Groupo Farma, 2012 43Table 13: Healthcare Spending, Venezuela, Patients Share (%), 2005-2010 54Table 14: Price Trend for Medicines and Medical Devices (%), Venezuela, 2008-2011 55Table 15: GDP Per Capita ($), Venezuela, 2006-2011 74Table 16: GDP Per Capita ($), Venezuela, Forecast, 2012-2020 75Table 17: GDP, Venezuela, Annual Growth (%), 2006-2011 76Table 18: GDP, Venezuela, Annual Growth (%), Forecast, 2012-2020 77Table 19: GNI Per Capita ($), Venezuela, 2005-2010 78Table 20: Average Consumer Price Index, Venezuela, 2006-2011 79Table 21: Average Consumer Price Index, Venezuela, Forecast, 2012-2020 80Table 22: Average Consumer Price, Venezuela, Annual Change (%), 2006-2011 81Table 23: Average Consumer Price, Venezuela, Annual Change (%), Forecast, 2012-2020 82Table 24: Currency Exchange Rate (VEB/$), Venezuela, 2005-2007 83Table 25: Currency Exchange Rate (VEF/$), Venezuela, 2008-2011 84Table 26: Foreign Direct Investment ($bn), Venezuela, 2005-2010 85Table 27: Foreign Exchange Reserves ($bn), Venezuela, 2006-2011 86Table 28: Imports of Goods and Services ($bn), Venezuela, 2006-2011 87Table 29: Exports of Goods and Services ($bn), Venezuela, 2006-2011 88Table 30: General Government Structural Balance ($bn), Venezuela, 2006-2011 89Table 31: General Government Structural Balance ($bn), Venezuela, Forecast, 2012-2020 90Table 32: Government Gross Debt ($bn), Venezuela, 2006-2011 91Table 33: Government Gross Debt ($bn), Venezuela, Forecast, 2012-2020 92Table 34: Major Industries, Venezuela, Gross Domestic Product ($bn), 2011 93Table 35: Population (m), Venezuela, 2006-2011 95Table 36: Population (m), Venezuela, Forecast, 2012-2020 96Table 37: Urban and Rural Population, Venezuela, Share (%), 2005-2010 97Table 38: Age Groups, Venezuela, Population Distribution (%), 2006-2011 99Table 39: Age Groups, Venezuela, Population Distribution (%), Forecast, 2012-2020 100Table 40: Births (Per 1,000 Population), Venezuela, 2006-2011 101Table 41: Births (Per 1,000 Population), Venezuela, Forecast, 2012-2020 102
  • Table 42: Mortality (Per 1,000 Population), Venezuela, 2006-2011 103Table 43: Mortality (Per 1,000 Population), Venezuela, Forecast, 2012-2020 104Table 44: Major Causes of Mortality (Number of Deaths, ‘000s), Venezuela, 2008 106Table 45: Children Table 46: Immunization Rate (%), Venezuela, 2005-2010 108Table 47: Major Causes of Male Mortality (Number of Deaths, ‘000s), Venezuela, 2008 109Table 48: Major Causes of Female Mortality (Number of Deaths, ‘000s), Venezuela, 2008 110Table 49: Gender Ratio (Males Per 100 Females), Venezuela, 2006-2011 111Table 50: Life Expectancy at Birth (Years), Venezuela, 2006-2011 112Table 51: Levels of School Education, Venezuela, Enrolment Rate (%), 2005-2010 114Table 52: Levels of Education, Venezuela, Students Enrolled, 2005-2010 114Table 53: Unemployment Rate (%), Venezuela, 2006-2011 115Table 54: Employment Sector, Venezuela, Employee (‘000s), 2011 116Table 55: Major Diseases, Venezuela, DALY (Per 100,000 Population), 2004 117Table 56: Public Hospitals, Venezuela, 2005-2010 119Table 57: Hospitals by Standard of Care, Venezuela, Share (%), 2010 120Table 58: Ambulatory Facilities, Venezuela, Urban and Rural Share (%), 2010 121Table 59: Hospitals by Bed Size, Venezuela, Share (%), 2010 122Table 60: Diagnostic Facilities, Venezuela, 2005-2010 123Table 61: Hospital Beds (Per 1,000 Population), Venezuela, 2005-2010 124Table 62: Number of Physicians (Per 10,000 Population), Venezuela, 2005-2010 125Table 63: Environmental Attributable Deaths (Per 100,000 Population), Venezuela, 2004 126Table 64: PM10 (micrograms per cubic meter), Venezuela, 2005-2010 127Table 65: CO2 Emissions (Million Tons), Venezuela, 2005-2010 129Table 66: Healthcare Expenditure (% of GDP), Venezuela, 2005-2010 130Table 67: Healthcare Expenditure, Venezuela, Public-Private Share (%), 2005-2010 1311.2 List of FiguresFigure 1: Pharmaceutical Market ($bn), Venezuela, 2006-2011 12Figure 2: Pharmaceutical Market ($bn), Venezuela, Forecast, 2012-2020 13Figure 3: Distribution Channels, Venezuela, 2011 15Figure 4: Drivers and Barriers, Healthcare Market, Venezuela, 2011 48Figure 5: History of the Healthcare System, Venezuela, 2011 51Figure 6: Healthcare Spending, Venezuela, Patients Share (%), 2005-2010 54Figure 7: Price Trend for Medicines and Medical Devices (%), Venezuela, 2008-2011 55Figure 8: Registration Procedure for New Drug, Venezuela, 2012 57Figure 9: Patent Approval Process, Venezuela, 2012 61Figure 10: Trademark Approval Process, Venezuela, 2012 63Figure 11: Clinical Trial Regulation Process, Venezuela, 2012 65Figure 12: Format of Advertisement, Venezuela, 2012 67Figure 13: GDP Per Capita ($), Venezuela, 2006-2011 74Figure 14: GDP Per Capita ($), Venezuela, Forecast, 2012-2020 75Figure 15: GDP, Venezuela, Annual Growth (%), 2006-2011 76
  • Figure 16: GDP, Venezuela, Annual Growth (%), Forecast, 2012-2020 77Figure 17: GNI Per Capita ($), Venezuela, 2005-2010 78Figure 18: Average Consumer Price Index, Venezuela, 2006-2011 79Figure 19: Average Consumer Price Index, Venezuela, Forecast, 2012-2020 80Figure 20: Average Consumer Price, Venezuela, Annual Change (%), 2006-2011 81Figure 21: Average Consumer Price, Venezuela, Annual Change (%), Forecast, 2012-2020 82Figure 22: Currency Exchange Rate (VEB/$), Venezuela, 2005-2007 83Figure 23: Currency Exchange Rate (VEF/$), Venezuela, 2008-2011 84Figure 24: Foreign Direct Investment ($bn), Venezuela, 2005-2010 85Figure 25: Foreign Exchange Reserves ($bn), Venezuela, 2006-2011 86Figure 26: Imports of Goods and Services ($bn), Venezuela, 2006-2011 87Figure 27: Exports of Goods and Services ($bn), Venezuela, 2006-2011 88Figure 28: General Government Structural Balance ($bn), Venezuela, 2006-2011 89Figure 29: General Government Structural Balance ($bn), Venezuela, Forecast, 2012-2020 90Figure 30: Government Gross Debt ($bn), Venezuela, 2006-2011 91Figure 31: Government Gross Debt ($bn), Venezuela, Forecast, 2012-2020 92Figure 32: Major Industries, Venezuela, GDP ($bn), 2011 93Figure 33: Population (m), Venezuela, 2006-2011 95Figure 34: Population (m), Venezuela, Forecast, 2012-2020 96Figure 35: Urban and Rural Population, Venezuela, Share (%), 2005-2010 97Figure 36: Age Groups, Venezuela, Population Distribution (%), 2006-2011 99Figure 37: Age Groups, Venezuela, Population Distribution (%), Forecast, 2012-2020 100Figure 38: Births (Per 1,000 Population), Venezuela, 2006-2011 101Figure 39: Births (Per 1,000 Population), Venezuela, Forecast, 2012-2020 102Figure 40: Mortality (Per 1,000 Population), Venezuela, 2006-2011 103Figure 41: Mortality (Per 1,000 Population), Venezuela, Forecast, 2012-2020 104Figure 42: Major Causes of Mortality (Number of Deaths, ‘000s), Venezuela, 2008 105Figure 43: Children Figure 44: Immunization Rate (%), Venezuela, 2005-2010 108Figure 45: Major Causes of Male Mortality (Number of Deaths, ‘000s), Venezuela, 2008 109Figure 46: Major Causes of Female Mortality (Number of Deaths, ‘000s), Venezuela, 2008 110Figure 47: Gender Ratio (Males Per 100 Females), Venezuela, 2006-2011 111Figure 48: Life Expectancy at Birth (Years), Venezuela, 2006-2011 112Figure 49: Levels of School Education, Venezuela, Enrolment Rate (%), 2005-2010 113Figure 50: Levels of Education, Venezuela, Students Enrolled, 2005-2010 114Figure 51: Unemployment Rate (%), Venezuela, 2006-2011 115Figure 52: Employment Sector, Venezuela, Employee (‘000s), 2011 116Figure 53: Major Diseases, Venezuela, DALY (Per 100,000 Population), 2004 117Figure 54: Public Hospitals, Venezuela, 2005-2010 119Figure 55: Hospitals by Standard of Care, Venezuela, Share (%), 2010 120Figure 56: Ambulatory Facilities, Venezuela, Urban and Rural Share (%), 2010 121Figure 57: Hospitals by Bed Size, Venezuela, Share (%), 2010 122Figure 58: Diagnostic Facilities, Venezuela, 2005-2010 123
  • Figure 59: Hospital Beds (Per 1,000 Population), Venezuela, 2005-2010 124Figure 60: Number of Physicians (Per 10,000 Population), Venezuela, 2005-2010 125Figure 61: Environmental Attributable Deaths (Per 100,000 Population), Venezuela, 2004 126Figure 62: PM10 (Micrograms Per Cubic Meter), Venezuela, 2005-2010 127Figure 63: CO2 Emissions (Million Tons), Venezuela, 2005-2010 129Figure 64: Healthcare Expenditure (% of GDP), Venezuela, 2005-2010 130Figure 65: Healthcare Expenditure, Venezuela, Public-Private Share (%), 2005-2010 131Figure 66: Opportunities and Challenges, Healthcare Market, Venezuela, 2012 135Contact: sales@reportsandreports.com for more information.